A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have a diagnosis of NSCLC with at least 1 measurable lesion
Participants Must Not:
Participant must not have had previous treatment with osimertinib or third generation EGFR TKIs
Participant must not have experienced a heart attack, unstable angina, or stroke, within 6 months prior to enrollment
Participant must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism during the 3 months prior to study enrollment
Participant must not have a bowel obstruction, Crohn's disease, ulcerative colitis, chronic diarrhea or a history of gastrointestinal perforation and/or fistula within 6 months prior to enrollment
Participant must not have uncontrolled hypertension
Participant must not be receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to enrollment
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo